文献速递前列腺癌前列腺增生与排尿功能障碍男科与性医学

局灶消融与全腺体消融对前列腺癌性功能及尿控的影响

Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence.
PubMed 文献 · J Urol · 2020-08-17

本研究比较前列腺癌局灶消融与全腺体消融后勃起功能和尿控的差异。2009至2018年间346例接受高强度聚焦超声或冷冻治疗的患者中,195例局灶治疗和105例全腺体治疗纳入分析。局灶治疗是3个月和12个月性功能恢复的最重要相关因素,也是尿控的唯一相关因素。

要点

  • 局灶消融是3个月和12个月性功能恢复的最重要相关因素。
  • 局灶消融是尿控恢复的唯一相关因素。
  • 倾向性评分匹配后结果仍显著。

核心结论

  • 局灶消融而非全腺体治疗是前列腺癌高强度聚焦超声和冷冻治疗后性功能和尿控更好恢复的最重要相关因素。

研究设计与样本

  • 回顾性研究,2009至2018年346例接受高强度聚焦超声或冷冻治疗的前列腺癌患者,排除后195例局灶治疗和105例全腺体治疗纳入分析。

主要发现

  • 多变量模型中局灶治疗是3个月(OR 7.7)和12个月(OR 3.9)性功能的最重要相关因素。
  • 局灶治疗组与全腺体治疗组3个月中位IIEF-5评分分别为12和5(p<0.001),12个月分别为13和9(p=0.04)。
  • 局灶治疗是尿控的唯一相关因素(OR 0.7,p<0.001)。
  • 倾向性评分匹配后结果仍显著。

关键数值与推荐

  • 尿控定义为不使用尿垫,性功能定义为勃起足以进行性交。
  • 基线I-PSS和IIEF-5评分无显著差异。

临床怎么用

  • 对于适合局灶消融的前列腺癌患者,局灶消融可能比全腺体消融更好地保留性功能和尿控。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Focal instead of whole gland ablation for prostate cancer has been proposed to decrease treatment morbidity. We sought to determine differences in erectile function and urinary continence after focal and whole gland ablation for prostate cancer. MATERIALS AND METHODS: From 2009 to 2018, 346 patients underwent high intensity focused ultrasound or cryotherapy for prostate cancer. Urinary continence was defined as use of no pads and sexual potency as enough erection for sexual penetration. Logistic regressions to treatment groups and covariates age, prostate specific antigen, International Society of Urological Pathology grading, prostate volume and energy modality were performed to access the effect of focal therapy in sexual potency and urinary continence after 3 and 12 months. IIEF-5 (International Index of Erectile Function) and I-PSS (International Prostate Symptom Score) questionnaires were evaluated. Propensity score matching was performed to adjust for potential baseline differences between groups. RESULTS: After exclusion, 195 post-focal therapy and 105 post-whole gland therapy patients were included in analysis. No significant difference was seen in baseline I-PSS and IIEF-5 scores. In multivariate models focal therapy was the most important factor related to sexual potency at 3 (OR 7.7) and 12 months (OR 3.9). Median IIEF-5 score at 3 months was 12 and 5 (p <0.001), and at 12 months was 13 and 9 (p=0.04) in focal therapy and whole gland therapy groups, respectively. Focal therapy was the only factor related to continence (OR 0.7, p <0.001). Results remained significant after propensity score matching. CONCLUSIONS: Focal ablation instead of whole gland therapy is the most important factor related to better sexual and urinary continence recovery after high intensity focused ultrasound and cryotherapy for prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Borges RC, Tourinho-Barbosa RR, Glina S, et al. Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence. J Urol. 2020. PMID: 33119421. doi:10.1097/JU.0000000000001327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。